We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Bristol Myers Squibb Co | NYSE:BMY | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.065 | 0.15% | 43.965 | 44.26 | 43.895 | 43.92 | 6,334,648 | 19:45:33 |
From May 2019 to May 2024
By Colin Kellaher
Dragonfly Therapeutics Inc. on Monday said it has expanded its research collaboration with Bristol-Myers Squibb Co. to include immunotherapies for multiple sclerosis and neuro-inflammation targets.
The privately held company said it will grant Bristol-Myers the option to license exclusive worldwide intellectual-property rights to multiple candidates developed using its proprietary platform for multiple new targets.
Dragonfly said it will receive a $55 million upfront payment and will be eligible to receive additional payments based on development, regulatory and sales milestones, along with royalties on sales of approved products.
Dragonfly in 2017 formed a five-year strategic collaboration with Celgene Corp. targeting oncology and autoimmune diseases. Bristol-Myers completed its $74 billion acquisition of Celgene last year.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
July 06, 2020 10:10 ET (14:10 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Bristol Myers Squibb Chart |
1 Month Bristol Myers Squibb Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
